BIO Stock: Price, Earnings History and SEC Filings
Bio-Rad Laboratories, Inc. (BIO) last traded at $372.18, down 3.18% on the latest session and down 1.5% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $2.62 against an analyst estimate of $2.34, a beat of 12.0%.
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
BIO earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 4, 2026 | $2.62 | $2.34 | +11.97% |
| Mar 2026 | Apr 30, 2026 | $1.89 | $2.77 | -31.77% |
| Dec 2025 | Feb 12, 2026 | $2.51 | $2.57 | -2.33% |
| Sep 2025 | Oct 29, 2025 | $2.26 | $2.30 | -1.74% |
BIO beat the analyst EPS estimate in 1 of its last 4 reported quarters. Source: Nasdaq.
How BIO reacts to earnings
Across its last 8 earnings releases, BIO moved 8.4% on average the next session, in either direction. It rose after 3 of 8 reports.
| Report date | Released | Next-session move |
|---|---|---|
| 2026-08-04 | After close | +4.50% |
| 2026-04-30 | After close | -8.41% |
| 2026-02-12 | After close | -12.26% |
| 2025-10-29 | After close | -4.65% |
| 2025-07-31 | After close | +17.63% |
| 2025-05-01 | After close | -1.70% |
| 2025-02-13 | After close | -9.53% |
| 2024-10-30 | After close | +8.35% |
Based on the dates of earnings-release 8-K filings (SEC EDGAR) and daily closing prices (Yahoo Finance). Past reactions do not predict future ones.
BIO financial history
| Fiscal year | Revenue | Net income | Free cash flow | Net margin | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | $2.6B | $760M | $375M | 29.4% | $27.85 |
| 2024 | $2.6B | -$1.8B | $290M | -71.9% | $-65.36 |
| 2023 | $2.7B | -$637M | $218M | -23.9% | $-21.82 |
| 2022 | $2.8B | -$3.6B | $82M | -129.5% | $-121.79 |
| 2021 | $2.9B | $4.3B | $536M | 145.6% | $140.83 |
| 2020 | $2.5B | $3.8B | $476M | 149.8% | $126.47 |
| 2019 | $2.3B | $1.8B | $359M | 76.1% | $58.27 |
| 2018 | $2.3B | $366M | $156M | 16.0% | $12.10 |
Source: annual figures from 10-K filings on SEC EDGAR. The year shown is the calendar year the fiscal year ended. Free cash flow is operating cash flow minus capital spending.
Latest SEC filings for BIO
- 10-Q · Aug 4, 2026
- 8-K · Aug 4, 2026Results of operations, Regulation FD disclosure, Financial statements and exhibits
- 10-Q · Apr 30, 2026
- 8-K · Apr 30, 2026Results of operations, Regulation FD disclosure, Financial statements and exhibits
- 8-K · Apr 24, 2026Officer or director change, Shareholder vote, Financial statements and exhibits
- DEF 14A · Mar 25, 2026
- 8-K · Feb 19, 2026Regulation FD disclosure
- 10-K · Feb 13, 2026
- 8-K · Feb 12, 2026Results of operations, Regulation FD disclosure, Financial statements and exhibits
- 10-Q · Oct 29, 2025
Insider filing activity
BIO insiders filed 14 Form 4 reports in the last 90 days. A Form 4 is how directors and executives disclose purchases, sales and grants of company stock. See the individual filings on SEC EDGAR. Many Form 4 filings are routine, such as scheduled sales or option exercises, so check each filing before drawing a conclusion.
Source: SEC EDGAR.
BIO news
- Bio Rad Laboratories (BIO) Stock Looks Fully Valued After 49% Five Year FallOct 31, 2026 · finance.yahoo.com
- Bio Rad Laboratories (BIO) Stock Dropped, What Is Behind The Fresh Attention?Oct 31, 2026 · finance.yahoo.com
- Nathan Fielder Meets Ryan ElHosseiny: The Science Behind “The Strip Club” and “Who’s on First” in You Can See EverythingOct 30, 2026 · finance.yahoo.com
- Will TXG Stock Ever Get Back To Its Old High?Oct 30, 2026 · trefis.com
- Bio-Rad to Participate in Fireside Chat During UBS Global Healthcare ConferenceOct 29, 2026 · finance.yahoo.com
- Reaction Monitoring - Global Strategic Business Report: Secure Share of the $2 Billion 2030 Market as Tariffs Reshape Danaher, Bruker, Bio-Rad, Waters, and Shimadzu StrategiesOct 29, 2026 · finance.yahoo.com
- Long-Read Full-Length cDNA Sequencing Global Market Report 2026 | Capitalize on 18.9% CAGR and Single-Cell Demand With PacBio, Oxford Nanopore, 10x Genomics and QIAGENOct 29, 2026 · finance.yahoo.com
- Microarray Scanners - Global Strategic Business Report 2026: Capitalize on $1.6 Billion Industry Revenue by 2032 | Thermo Fisher Scientific, Agilent Technologies, Illumina, and Bio-Rad Laboratories DominateOct 28, 2026 · finance.yahoo.com
About Bio-Rad Laboratories, Inc.
Bio-Rad Laboratories, Inc. (BIO) is a US-listed public company on NYSE. The SEC classifies its business as Laboratory Analytical Instruments. It is incorporated in DE. Its fiscal year ends in December.